Tiverton Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Tiverton Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.57M	Hold	19,591	–	–	0.05%	237
2019 Q2	$1.42M	Sell	19,591 -3,629	-16%	-$278K	0.05%	230
2019 Q1	$2.17M	Hold	23,220	–	–	0.09%	166
2018 Q4	$1.69M	Sell	23,220 -17,455	-43%	-$1.34M	0.1%	131
2018 Q3	$3.56M	Sell	40,675 -5,898	-13%	-$593K	0.17%	101
2018 Q2	$4.59M	Buy	46,573 +13,573	+41%	+$1.35M	0.23%	90
2018 Q1	$3.93M	Buy	+33,000	New	+$4.25M	0.27%	87

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Tiverton Asset Management's ALNY Position: Q3 2019 in Review

Tiverton Asset Management held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2019 at 19,591 shares worth $1.57M. The position accounts for 0.05% of the portfolio, ranked #237.

Tiverton Asset Management first reported a position in ALNY in Q1 2018 and has held it in 7 quarters since. The position peaked at $4.59M in Q2 2018. 281 funds tracked by Wall St. Rank hold ALNY as of Q3 2019.

Tiverton Asset Management held 19,591 shares of Alnylam Pharmaceuticals worth $1.57M as of Q3 2019.
Tiverton Asset Management left its Alnylam Pharmaceuticals share count unchanged in Q3 2019.
Alnylam Pharmaceuticals made up 0.05% of Tiverton Asset Management's portfolio in Q3 2019, its #237 holding.
Tiverton Asset Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and has held it in 7 quarters since.
Tiverton Asset Management's Alnylam Pharmaceuticals position peaked at $4.59M in Q2 2018.
281 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.